Senior Congress leader Shashi Tharoor on Sunday said that the emergency approval to COVID-19 vaccine--Covaxin is premature and could be dangerous as it is still under phase 3 trial. He urged Union Health Minister Dr Harsh Vardhan to wait till full trials of the vaccine are completed.
Taking to Twitter, Member of Parliament from Kerala's Thiruvananthapuram said, "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous."
He further urged Union Health Minister Dr Harsh Vardhan to avoid Covaxin till full trials are over.
"Union Health Minister Dr Harsh Vardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime," he added in the tweet.
Earlier today, COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in an emergency situation, said DCGI.
"After adequate examination, Central Drugs Standard Control Organisation(CDSCO) has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial," said VG Somani, DCGI, during a media briefing today.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)